Phoenix, Arizona-(Newsfile Corp.-June 1, 2022)-Stock Day Podcast has recently been a leader in development and sales, Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or “the Company”). Welcomed. Providing innovative, widely effective pressure-based equipment, consumables, and specialty testing services for the global life sciences market and other industries. Our CEO, Richard T. Schumacher, has joined Stockday’s host, Server Copley.
Mr. Copley began, “First, please tell us about PBI.”
“Pressure BioSciences is a very innovative company,” Schumacher explained. “We have learned how to apply its transforming power, which moves at the speed of sound in various fields, to utilize extreme pressure with exquisite precision and use it safely. It is in scientific laboratories and various commerce. A gentle giant who accomplishes many things, an industry that now relies on aggressive or harmful heat, cold, and chemicals to achieve. “He continues: “Our high-pressure breakthrough application is from the preparation of all kinds of samples for scientific analysis to the production and preparation of biopharmacy optimized for efficacy, and the latest technology platform, Ultra. It extends to Shear Technology ™ (“UST ™”). Preparation of nanoemulsions and shelf-stable foods that have historically gone beyond commercial scope. “
Mr. Copley further asked: “We are certainly listening and would like to know more about the successful launch of your UST Early Access program. Please explain!”
“Our latest platform innovation, UST, is currently being introduced in the first commercial applications. UST puts oil and water emulsions under very high pressure and is dynamic with nanogap orifices. It drives the emulsion through a control valve to produce a powerful and accurate product. The size of the oil droplets in the nanoemulsion has become very small, “says Schumacher. “To date, UST has issued seven patents, two of which are in the United States, and more are expected to follow.”
Schumacher goes on to say: “The oils in these emulsions usually contain valuable active ingredients such as pharmaceuticals and dietary supplements, functional cosmetic ingredients, and nutrients in important foods and beverages. At droplet size, these ingredients are Suddenly it becomes almost 100% biologically available, allowing the body to absorb them much more efficiently, but the solution becomes visibly transparent, increasing the benefits of aroma, taste and texture. UST also shreds many microbial inclusions, providing foods, beverages, and many other products with significantly extended room temperature and cold chain shelf life and stability. “
“Due to urgent demand, we recently decided to announce an early access program for the UST platform, which is a small number of companies that can’t wait to wait for the full commercial release planned for 4. To provide services to.th “In the 2022 quarter, we will select 4-5 companies in the coming weeks and months. To show the world what our team can achieve with the innovative Ultra,” Schumacher said. Working with them to pave the way. Shear technology platform, “he continued.
Mr. Copley further focused on: “Who is safer health care and why did you choose them as the first customer of the UST Early Access program?”
“Safer Medical is a small, innovative company in Montana that specializes in personal care products. It’s basically led by a former Vietnam veteran who wants to give back,” Schumacher said, and Safer Medical is a CBD product. He added that he approached Pressure BioSciences in. It was designed to require improved bioavailability. “We started with a few first demos and then started working with them, and we changed the formula, quickly penetrated using Ultra Sheer technology and are very biologically available. Dramatically improved their products by making them nanoemulsions. “
“We have decided to introduce Safer Medical as our first customer. The initial scale of this product is perfect for pre-launch UST processing capacity, so we have finished compounding work. We are currently piloting for market testing. We plan to move on to the run. By the fourth quarter, we plan to begin manufacturing vials for commercial sale of this product. ” “We expect this to be the first commercial product on the market with Ultra Sheer technology.”
“Are you planning to announce additional members of the UST Early Access Program?” Asked Mr. Copley.
“The Early Access program will support four to five companies,” Schumacher said, adding that he is currently in talks with well-known cosmetics companies and companies in the fields of agriculture, wellness and dietary supplements. .. “We plan to contract with these companies in the coming weeks and months, and by the end of 2022 we plan to bring several more products that incorporate the benefits of UST to the market.”
Schumacher concludes: “UST will strongly differentiate these companies’ products into leadership roles in their respective markets. From now on, UST’s commercial leasing and licensing model will dramatically launch PBI’s revenue streams. It is expected that a new trajectory from the beginning to the middle of 2023. “
To conclude the interview, Schumacher would like to thank our shareholders for their support as we continue to work on the commercialization of UST. He also encouraged listeners to keep up to date with the company’s current projects and upcoming announcements.
To hear the full Schumacher interview, follow the link to the podcast: https://audioboom.com/posts/8093822-pressure-biosciences-discusses-launch-of-early-access-program-for-ultra -shear- Technology Forza
Investors Hangout is a sponsor of “Stock Day” and Stock Day Media encourages listeners to visit the company’s bulletin board at https://investorshangout.com/.
About Pressure Bioscience
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, widely effective pressure-based solutions for life sciences and other industries around the world. Our products are based on the unique properties of both constant (ie static) and alternating (ie pressure cycling techniques, or PCT) hydrostatic pressure. PCT is a patented realization technology platform that uses alternating cycles of hydrostatic pressure between ambient pressure and ultra-high levels to safely and reproducibly control biomolecular interactions (cytolysis, living organisms). Molecular extraction, etc.). Our main focus is on PCT-based products for biomarker and target discovery, drug design and development, biotherapy characterization and quality control, soil and plant biology, forensic medicine, and bioterrorism protection applications. Is the development of. In addition, major new market opportunities have emerged in the use of pressure-based technologies in the following areas: (1) Biopharmaceutical Services Division using recently patented technology (“BaroFold” technology) from BaroFold, Inc., and (2) recently patented scalable, highly efficient pressure-based ultra-shear technology. Using the (“UST”) platform, (i) otherwise create stable nanoemulsions of immiscible liquids (eg oil and water) and (ii) use existing non-thermal techniques. To prepare higher quality, homogenized, long shelf life or stable low acid liquid foods at room temperature that cannot be stored effectively.
Description of future prospects
This press release contains forward-looking statements. These statements relate to future events or future financial performance and are known and unknown risks, uncertainties, and actual results, levels of activity, performance, or outcomes of the Company or the industry are future results, levels. In some cases, “may”, the activity, performance, or outcome expressed, implied, or inferred by these forward-looking statements, including other factors that may cause a significant difference from. Descriptions of future prospects in terms such as “do”, “should”, “done”, “will”, “expect”, “plan”, “intention”, “expect” Can be identified. “Believe”, “estimate”, “predict”, “predict”, “potential”, “continue”, or the denial of such or other equivalent terms. These statements are only predictions based on current expectations and predictions about future events. You should not place excessive trust in these statements. Various factors need to be specifically considered when evaluating these statements. Actual events or consequences may vary significantly. Due to these and other factors, actual results may differ materially from forward-looking statements. Risks, uncertainties, and other factors include the risks described under the “Risk Factors” heading in our annual report on Form 10-K for the fiscal year ended December 31, 2021. Uncertainties and other submitted reports include, but are not limited to. Sometimes by company t ime with SEC. We undertake no obligation to update the information contained in this release except as required by law.
For more information on PBI and this press release, please click the following link.
http://www.pressurebiosciences.com
Visit us on Facebook, LinkedIn, and Twitter.
Investor contact information
Richard T. Schumacher, President and CEO (T) 508-230-1828
John B. Hollister, Director of Marketing and Sales (F) 508 230-1829
About the “Stock Day” Podcast
Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. While educating investors, we work with penny stocks and OTC companies to provide transparency and clarification of undervalued and unsold microcap stocks in the market. Stock Day provides businesses with customized solutions for news distribution in domestic and international media. Stock Day Podcasts are the number one radio show of its kind in the United States.
sauce:
Stock day media
(602) 821-1102
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/126142.
